<br>        Inclusion Criteria:<br><br>          -  Patients with non-resectable, histologically confirmed, synchronous or metachronous<br>             colorectal liver metastases. Patients with non-resectable metastases are defined as;<br>             patients with five or more liver metastases; and/or patients with liver metastases<br>             that are technically non-resectable (local surgeon in cooperation with local<br>             radiologist will define non-resectability on the basis of remaining functional liver<br>             tissue, infiltration of all liver veins, infiltration of both liver arteries, both<br>             portal branches or both bile ducts).<br><br>          -  Patients with simultaneous liver metastases are eligible, if the primary tumor has<br>             been resected at least 1 month prior to chemotherapy.<br><br>          -  Karnofsky Performance Status = 80<br><br>          -  Informed consent<br><br>          -  Adequate bone marrow function, liver and renal function (neutrophils > 1.5 x 10^9/l;<br>             thrombocytes > 100 x 10^9/l; hemoglobin > 8.0 g/l; bilirubin = 1.5 x upper limit of<br>             normal [ULN] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT<br>             < 5 x UNL; serum creatinine = 1.5 x UNL)<br><br>          -  Age = 18 years<br><br>        Exclusion Criteria:<br><br>          -  Any evidence of extrahepatic metastases, lymph node metastases and primary tumor<br>             recurrence<br><br>          -  Prior chemotherapy (except adjuvant chemotherapy with an interval of = 6 months)<br><br>          -  Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy<br><br>          -  Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or<br>             port implantation) = 4 weeks before study entry<br><br>          -  Concurrent systemic immune therapy, chemotherapy, or hormone therapy<br><br>          -  Investigational agents or participation in clinical trials within 30 days before<br>             start of the treatment in study<br><br>          -  Clinically relevant coronary disease or myocardial infarction within 12 months before<br>             study entry<br><br>          -  Peripheral neuropathy > CTC grade I<br><br>          -  Inflammatory bowel disease<br><br>          -  Previous malignancy (except colorectal cancer, history of basal cell carcinoma of<br>             skin or pre-invasive carcinoma of the cervix with adequate treatment)<br><br>          -  History of severe psychiatric illness<br><br>          -  Drug or alcohol abuse<br><br>          -  Breast feeding or pregnant women, no effective contraception if risk of conception<br>             exists (male and female patients)<br>